Raptor Pharmaceutical Launches QUINSAIR™ in Europe
April 11, 2016 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and...
Raptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review
March 21, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI®...
Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin
March 16, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as...
Raptor Pharmaceutical to Participate in the Cowen and Company 36th Annual Health Care Conference
March 01, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
Raptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy Activities
February 29, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its support of Rare Disease Week, beginning February 29, 2016, with a series of activities...
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update
February 25, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ET
February 18, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2015 financial results on...
Raptor Pharmaceutical to Participate in the Leerink Partners 5th Global Healthcare Conference
February 08, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
January 25, 2016 07:05 ET
|
Raptor Pharmaceutical Inc
Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...
NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD
November 16, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...